CA-ENEVATE
14.1.2020 12:02:06 CET | Business Wire | Press release
Enevate , a pioneer in advanced silicon-dominant lithium-ion (Li-ion) battery technology capable of extreme fast charging for electric vehicles (EVs), announced its new 4th generation technology optimized for high volume commercialization and manufacturing at gigafactory scale. Enevate is providing a solution to a difficult problem for automotive OEMs and EV battery manufacturers – providing extreme fast charging with high energy density and at lower material cost than conventional Li-ion batteries, while being compatible with existing battery fabrication facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200114005035/en/
The new XFC-Energy™ technology achieves 5-minute charging to 75 percent capacity with 800 Wh/L cell energy density. Today’s conventional large-format Li-ion EV cells are at 500-600 Wh/L and typically take over 1 hour to charge.
“Mass EV adoption by consumers and fleet owners will depend to a large degree on advanced battery technology that will remove current barriers to entry such as long charging times and limited range,” said Christian Noske , Chairman of Alliance Ventures (Renault-Nissan-Mitsubishi). “Enevate is a key enabler for electric vehicles that are affordable, easy and quick to charge, and clean.”
Dr. John Goodenough , a recipient of the 2019 Nobel Prize in chemistry for groundbreaking work in the development of lithium-ion batteries and who has served on Enevate’s Advisory Board since 2010, added: “I salute the Enevate team for reaching this next important step in fulfilling the company’s mission to develop and commercialize innovative battery technologies to accelerate the adoption of electrified mobility.”
Enevate’s 4th generation XFC-Energy technology stands to be a game-changer for the EV industry, providing a path to produce extreme fast-charge EV batteries at low cost and high-volume production. Enevate is currently working with multiple automotive OEMs and EV battery manufacturers to commercialize its technology for 2024-2025 model year EVs, utilizing existing manufacturing infrastructure with minimal investment required, a core goal of its development.
Enevate’s 4th generation is the latest result of over 74 million hours of battery cell testing by Enevate’s scientists, 1 million meters of electrodes produced in the company’s R&D pilot line, and 2 billion test datapoints.
Enevate Founder and Chief Technology Officer Dr. Benjamin Park noted that Enevate’s XFC-Energy technology has been designed for large-format pouch, prismatic and cylindrical EV cells, utilizing its pure silicon anode paired with nickel-rich NCA, NCM and NCMA advanced cathodes.
“Enevate’s extreme fast charge technology enables a future where gas stations become drive-through EV charging stations – a win-win for consumers and the environment as electric vehicles replace those using gasoline,” Dr. Park said. “Enevate’s technology will help close the usability gap between today’s EVs and gas cars.”
Dr. Park will be discussing Enevate’s technology on January 15 at the Advanced Automotive Battery Conference in Weisbaden, Germany, in a presentation titled “Charging Ahead: Commercializing Fast-Charge Si-Dominant Li-ion Cells for EVs.”
XFC-Energy Technology Technical Details
- Cell technology scalable for large-format pouch, prismatic and cylindrical EV cells suitable for various battery module and pack architectures. Achieves 800 Wh/L and 340 Wh/kg in large-format EV cells.
- Pure silicon-dominant anode technology tunable with 10-60µm thickness and 1000-2000mAh/g that can be paired with NCA, NCM811, NCMA, low-cobalt, or other advanced cathode technologies.
- Continuous roll-to-roll anode manufacturing processes designed and capable of achieving over 80 meters per minute electrode production, over 10 GWh per electrode production line, with pure silicon anode rolls greater than 1 meter wide and longer than 5 kilometers in length sufficient for high volume gigafactory production, among other features.
- Lower anode material cost (dollar per kWh) than conventional and synthetic graphite.
- Transformative performance improvement, with five-minute charge to 75 percent of battery capacity, and, when paired with a high-nickel cathode, capable of over 1000 cycles using an EV drive cycle test and operation at -20˚C and below temperatures.
- Bottom line: Five-minute extreme fast charging, high energy density, low temperature operation, low cost and superior safety.
ABOUT ENEVATE (www.enevate.com)
Enevate develops and licenses advanced silicon-dominant Li-ion battery technology for electric vehicles (EVs), with a vision to charging EVs as fast as refueling gas cars and accelerating their mass adoption. With a portfolio of more than 200 patents issued and in process, Enevate’s pioneering advancements in silicon-dominant anodes and cells have resulted in battery technology that features five-minute extreme fast charging with high energy density, low temperature operation for cold climates, low cost and safety advantages over conventional Li-ion batteries.
Enevate’s vision is to develop and propagate EV battery technology that contributes to a clean and sustainable environment. The Irvine, California-based company has raised over $110 million from investors including Renault-Nissan-Mitsubishi (Alliance Ventures), LG Chem, Samsung, Mission Ventures, Draper Fisher Jurvetson, Tsing Capital, Infinite Potential Technologies, Presidio Ventures – a Sumitomo Corporation company, Lenovo, CEC Capital and Bangchak. Enevate®, the Enevate logo, XFC-Energy™, HD-Energy®, and eBoost® are registered trademarks of Enevate Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
